Hilz Max J, Canavese Francesca, de Rojas-Leal Carmen, Lee De-Hyung, Linker Ralf A, Wang Ruihao
Department of Neurology, University of Erlangen-Nuremberg, Schwabachanlage 6, 91054, Erlangen, Germany.
Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Clin Auton Res. 2025 Feb;35(1):59-73. doi: 10.1007/s10286-024-01073-w. Epub 2024 Oct 9.
Vagomimetic fingolimod effects cause heart rate (HR) slowing upon treatment initiation but wear off with sphingosine-1-phosphate receptor downregulation. Yet, prolonged HR slowing may persist after months of fingolimod treatment. We evaluated whether cardiovascular autonomic modulation differs before and 6 months after fingolimod initiation between patients with RRMS with and without initially prolonged HR slowing upon fingolimod initiation.
In 34 patients with RRMS, we monitored RR intervals (RRI) and blood pressure (BP), at rest and upon standing up before fingolimod initiation. Six hours and 6 months after fingolimod initiation, we repeated recordings at rest. At the three time points, we calculated autonomic parameters, including RRI standard deviation (RRI-SD), RRI-total-powers, RMSSD, RRI high-frequency [HF] powers, RRI and BP low-frequency (LF) powers, and baroreflex sensitivity (BRS). Between and among patients with and without prolonged HR slowing upon fingolimod initiation, we compared all parameters assessed at the three time points (analysis of variance [ANOVA] with post hoc testing; significance: p < 0.05).
Six hours after fingolimod initiation, all patients had decreased HRs but increased RRIs, RRI-SDs, RMSSDs, RRI-HF-powers, RRI-total-powers, and BRS; 11 patients had prolonged HR slowing. Before fingolimod initiation, these 11 patients did not decrease parasympathetic RMSSDs and RRI-HF-powers upon standing up. After 6 months, all parameters had reapproached pretreatment values but the 11 patients with prolonged HR slowing had lower HRs while the other 23 patients had lower parasympathetic RMSSDs and RRI-HF-powers, and BRS than before fingolimod initiation.
Our patients with prolonged HR slowing upon fingolimod initiation could not downregulate cardiovagal modulation upon standing up even before fingolimod initiation, and 6 months after fingolimod initiation still had more parasympathetic effect on HR while cardiovagal modulation and BRS were attenuated in the other 23 patients. Pre-existing parasympathetic predominance may cause prolonged HR slowing upon fingolimod initiation.
拟迷走神经作用的芬戈莫德效应在治疗开始时会导致心率(HR)减慢,但随着1 -磷酸鞘氨醇受体下调而逐渐消失。然而,在芬戈莫德治疗数月后,心率可能会持续减慢。我们评估了在开始使用芬戈莫德时,初始心率是否会延长的复发缓解型多发性硬化症(RRMS)患者在开始使用芬戈莫德之前和之后6个月心血管自主神经调节是否存在差异。
在34例RRMS患者中,我们在开始使用芬戈莫德之前,监测其静息和站立时的RR间期(RRI)和血压(BP)。在开始使用芬戈莫德后6小时和6个月,我们重复静息状态下的记录。在这三个时间点,我们计算自主神经参数,包括RRI标准差(RRI-SD)、RRI总功率、RMSSD、RRI高频[HF]功率、RRI和BP低频(LF)功率以及压力反射敏感性(BRS)。在开始使用芬戈莫德时心率是否延长的患者之间,我们比较了在三个时间点评估的所有参数(方差分析[ANOVA]及事后检验;显著性:p < 0.05)。
在开始使用芬戈莫德后6小时,所有患者的心率均下降,但RRI、RRI-SD、RMSSD、RRI-HF功率、RRI总功率和BRS均增加;11例患者心率持续减慢。在开始使用芬戈莫德之前,这11例患者在站立时副交感神经RMSSD和RRI-HF功率并未降低。6个月后,所有参数均恢复到治疗前水平,但11例心率持续减慢的患者心率较低,而其他23例患者的副交感神经RMSSD、RRI-HF功率和BRS均低于开始使用芬戈莫德之前。
我们的患者在开始使用芬戈莫德时心率持续减慢,即使在开始使用芬戈莫德之前站立时也无法下调心脏迷走神经调节,并且在开始使用芬戈莫德6个月后,对心率仍有更多的副交感神经作用,而其他23例患者的心脏迷走神经调节和BRS减弱。预先存在的副交感神经优势可能导致在开始使用芬戈莫德时心率持续减慢。